MUCORmycosis: unlocking better diagnosis and care for at-risk patients
Official title: Deciphering Immunopathogenesis of MUCORmycosis to ADVANCE Risk stratification, Diagnosis and Management of the Disease
Funded at Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · NIH-11364076 · Data updated 2026-11-12
A multi-institution program aims to understand how MUCORmycosis develops in people with risk factors like diabetes, steroids, or weakened immunity, and use that knowledge to improve diagnosis and treatment.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center NIH-funded |
| Lab location | 1 site (Torrance, United States) |
| Project start | July 1, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $2,243,207 |
| NIH project number | 5P01AI186818-02 |
| Project ID | NIH-11364076 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients at risk for mucormycosis, including those with diabetes, neutropenia, organ transplant recipients, or those on high-dose corticosteroids.
✕Less likely to help
The direct benefits may be limited for people without risk factors for mucormycosis or those not affected by the disease.
What this research studies
This NIH project brings together experts to study the immune response and fungal factors that drive mucormycosis, with the goal of creating faster tests and smarter therapies. Researchers will examine how Mucorales infections interact with patients’ bodies and why some people respond differently to treatment. The work includes developing new diagnostic assays and targeted treatment approaches that could guide clinicians in real time. Patients with immune suppression or recent surgeries may benefit from the advances once translated into clinical practice.
Why it matters
Potential benefit: If successful, patients with mucormycosis may get earlier, more accurate diagnoses and more effective, personalized treatments.
How similar studies have gone: Previous research in mucormycosis has identified important disease pathways, but this program aims to integrate findings into practical diagnostics and therapies.
Where this research is happening
-
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, United States Active
Researchers
- Principal investigator: Ibrahim, Ashraf S. — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Study coordinator: Ibrahim, Ashraf S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.